Beyond Neuroprotection: Context-Dependent Effects of GLP-1 Receptor Agonists on Seizure Susceptibility

Originally published in Epilepsia

Medications called glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are commonly used to treat type 2 diabetes and obesity. In addition to helping control blood sugar and support weight loss, researchers are becoming increasingly interested in the potential benefits of these drugs for brain health.

In this critical review of the literature, some studies suggest that these medications may protect brain cells and reduce inflammation. However, an important question remains: How do GLP-1 medications affect people who already have epilepsy or are at risk for seizures?

A recent study suggests that these medications do not affect all types of epilepsy in the same way. The study identified several factors that could influence how these medications affect brain activity and seizure susceptibility. For example, GLP-1 medications slow stomach emptying, which could affect how quickly some anti-seizure medications are absorbed into the bloodstream. Individual GLP-1 medications have different properties, including how long they remain active in the body which might impact people differently. Their effects on seizure activity may vary depending on the type of epilepsy, individual brain characteristics, and changes that occur during treatment.

More targeted research is needed to determine whether these medications are neurologically safe across different types of epilepsy and to identify individuals who may require closer monitoring.

Learn More | Back to All Epilepsy Research News